Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-12-12 Sale | 2025-12-16 6:36 pm | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,804 | $188.31 | $339,711 | 26,186 (Direct) | View |
| 2025-12-01 Sale | 2025-12-03 5:08 pm | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 467 | $195.84 | $91,457 | 44,121 (Direct) | View |
| 2025-11-07 Sale | 2025-11-12 4:45 pm | LIGAND PHARMACEUTICALS INC | LGND | Gray Nancy Ryan Director | 6,571 | $205.45 | $1,350,012 | 8,094 (Direct) | View |
| 2025-11-07 Sale | 2025-11-12 4:44 pm | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 4,179 | $205.45 | $858,576 | 30,724 (Direct) | View |
| 2025-11-03 Sale | 2025-11-05 5:22 pm | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 467 | $191.05 | $89,219 | 44,588 (Direct) | View |
| 2025-10-01 Sale | 2025-10-03 4:45 pm | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 467 | $179.44 | $83,800 | 45,055 (Direct) | View |
| 2025-09-23 Sale | 2025-09-24 5:11 pm | LIGAND PHARMACEUTICALS INC | LGND | Aryeh Jason Director | 10,000 | $170.81 | $1,708,088 | 125,908 (Indirect Direct) | View |
| 2025-09-02 Sale | 2025-09-04 5:47 pm | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 467 | $162.26 | $75,775 | 45,522 (Direct) | View |
| 2025-08-01 Sale | 2025-08-05 5:03 pm | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 467 | $131.88 | $61,586 | 45,989 (Direct) | View |
| 2025-07-10 Sale | 2025-07-11 6:17 pm | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 934 | $125 | $116,750 | 46,456 (Direct) | View |
| 2025-06-23 Sale | 2025-06-24 8:29 pm | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 500 | $114.08 | $57,042 | 31,903 (Direct) | View |
| 2025-06-10 Sale | 2025-06-12 5:51 pm | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 500 | $114.54 | $57,271 | 32,403 (Direct) | View |
| 2025-05-15 Sale | 2025-06-02 8:06 pm | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 1,000 | $104 | $104,000 | 32,903 (Direct) | View |
| 2025-05-09 Purchase | 2025-05-13 8:05 pm | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 9,510 | $105.2 | $1,000,456 | 161,234 (Direct) | View |
| 2025-05-09 Purchase | 2025-05-13 8:04 pm | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,500 | $104.06 | $156,090 | 27,932 (Direct) | View |
| 2025-03-04 Sale | 2025-03-06 6:55 pm | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 5,000 | $115.03 | $575,149 | 59,080 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-12-16 Exercise | 2025-12-18 4:19 pm | N/A 2032-05-05 | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 2,381 | $0 | 61,472 (Direct) | View |
| 2025-12-16 Exercise | 2025-12-18 4:19 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 181 | $103.42 | 61,472 (Direct) | View |
| 2025-12-16 Exercise | 2025-12-18 4:19 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 69 | $57.22 | 61,472 (Direct) | View |
| 2025-12-16 Exercise | 2025-12-18 4:19 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,194 | $52.84 | 61,472 (Direct) | View |
| 2025-12-16 Exercise | 2025-12-18 4:19 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 652 | $92.65 | 61,472 (Direct) | View |
| 2025-12-16 Exercise | 2025-12-18 4:19 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 285 | $63.62 | 61,472 (Direct) | View |
| 2025-12-05 Tax Withholding | 2025-12-09 8:06 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,862 | $184.87 | 27,990 (Direct) | View |
| 2025-12-08 Exercise | 2025-12-08 7:38 pm | N/A 2026-05-23 | LIGAND PHARMACEUTICALS INC | LGND | Aryeh Jason Director | 2,034 | $0 | 127,942 (Direct) | View |
| 2025-12-08 Exercise | 2025-12-08 7:38 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Aryeh Jason Director | 2,034 | $69.51 | 127,942 (Direct) | View |
| 2025-12-04 Gift | 2025-12-08 7:37 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 130 | $0 | 161,337 (Direct) | View |
| 2025-11-07 Exercise | 2025-11-12 4:45 pm | N/A 2029-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Gray Nancy Ryan Director | 6,571 | $0 | 8,094 (Direct) | View |
| 2025-11-07 Exercise | 2025-11-12 4:45 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Gray Nancy Ryan Director | 3,015 | $73.57 | 8,094 (Direct) | View |
| 2025-11-07 Exercise | 2025-11-12 4:45 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Gray Nancy Ryan Director | 3,556 | $66.19 | 8,094 (Direct) | View |
| 2025-11-07 Exercise | 2025-11-12 4:44 pm | N/A 2027-05-25 | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 4,179 | $0 | 30,724 (Direct) | View |
| 2025-11-07 Exercise | 2025-11-12 4:44 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 2,034 | $69.51 | 30,724 (Direct) | View |
| 2025-11-07 Exercise | 2025-11-12 4:44 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 2,145 | $66.13 | 30,724 (Direct) | View |
| 2025-11-06 Option Award | 2025-11-10 4:43 pm | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC Director 10% Owner | 9,000,000 | $9,000,000 | 9,000,000 (Direct) | View |
| 2025-09-22 Tax Withholding | 2025-09-24 5:10 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Zimmermann Martine Director | 115 | $170.77 | 4,443 (Direct) | View |
| 2025-08-10 Tax Withholding | 2025-08-12 4:34 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 1,325 | $150.06 | 30,811 (Direct) | View |
| 2025-07-01 Other | 2025-07-03 09:33 am | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC 10% Owner | 31,279 | $0 | 1,537,279 (Direct) | View |
| 2025-07-01 Conversion | 2025-07-03 09:33 am | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC 10% Owner | 1,500,000 | $10 | 1,537,279 (Direct) | View |
| 2025-07-01 Conversion | 2025-07-03 09:33 am | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC 10% Owner | 15,000 | $0 | 1,537,279 (Direct) | View |
Ownership | 2025-07-03 09:28 am | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC 10% Owner | 0 | $0 | 1,800,000 (Direct) | View |
| 2025-06-30 Other | 2025-07-02 7:32 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 233 | $91.08 | 32,369 (Direct) | View |
| 2025-06-30 Other | 2025-07-02 7:32 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 224 | $91.08 | 30,076 (Direct) | View |
| 2025-06-30 Other | 2025-07-02 7:31 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 233 | $91.08 | 161,700 (Direct) | View |
Ownership(A) | 2025-07-02 7:03 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 0 | $0 | 1,696 (Direct) | View |
| 2025-06-06 Option Award | 2025-06-10 7:39 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Gray Nancy Ryan Director | 6,992 | $0 | 13,877 (Direct) | View |
| 2025-06-06 Option Award | 2025-06-10 7:39 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Aryeh Jason Director | 6,992 | $0 | 141,691 (Direct) | View |
| 2025-06-06 Option Award | 2025-06-10 7:24 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 6,992 | $0 | 36,507 (Direct) | View |
| 2025-06-06 Option Award | 2025-06-10 7:21 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Zimmermann Martine Director | 6,992 | $0 | 10,341 (Direct) | View |
| 2025-06-06 Tax Withholding | 2025-06-10 7:21 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Zimmermann Martine Director | 188 | $105.99 | 10,341 (Direct) | View |
| 2025-06-06 Option Award | 2025-06-10 7:21 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Sabba Stephen L Director | 6,992 | $0 | 39,576 (Direct) | View |
| 2025-06-06 Option Award | 2025-06-10 7:21 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 6,992 | $0 | 53,173 (Direct) | View |
| 2025-06-06 Option Award | 2025-06-10 7:20 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Haas Jason Director | 6,992 | $0 | 12,389 (Direct) | View |
| 2024-08-10 Tax Withholding | 2025-06-02 8:06 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 897 | $100.16 | 32,903 (Direct) | View |
| 2025-01-17 Exercise | 2025-06-02 8:05 pm | N/A 2025-04-24 | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 2,406 | $0 | 46,181 (Direct) | View |
| 2025-01-17 Exercise | 2025-06-02 8:05 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 2,406 | $52.3 | 46,181 (Direct) | View |
| 2025-04-01 Exercise | 2025-04-16 09:34 am | N/A 2025-04-24 | LIGAND PHARMACEUTICALS INC | LGND | Sabba Stephen L Director | 2,406 | $0 | 32,584 (Direct) | View |
| 2025-04-01 Exercise | 2025-04-16 09:34 am | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Sabba Stephen L Director | 2,406 | $52.3 | 32,584 (Direct) | View |
| 2025-03-04 Option Award | 2025-03-06 6:55 pm | N/A 2035-03-04 | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 34,458 | $0 | 62,826 (Direct) | View |
| 2025-03-04 Option Award | 2025-03-06 6:55 pm | N/A 2035-03-04 | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 40,201 | $0 | 59,080 (Direct) | View |
| 2025-03-04 Option Award | 2025-03-06 6:54 pm | N/A 2035-03-04 | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 114,858 | $0 | 245,200 (Direct) | View |